Key Stats for Elevance Health Stock
- 52-Week Range: $274 to $408
- Current Price: $395
- Street Mean Target: $401
- Street High Target: $498
- Analyst Consensus: 12 Buys / 3 Outperforms / 7 Holds
- TIKR Model Target (Dec. 2030): $534
Elevance Health Beats Q1 Estimates by $1.76 Per Share and Raises Full-Year Guidance Amid Sector Recovery
Elevance Health (ELV) reported first-quarter 2026 adjusted diluted earnings per share of $12.58, beating the consensus estimate of $10.82, as the largest Blue Cross Blue Shield licensee in the United States delivered better-than-expected claims experience across its diversified insurance and healthcare services platform.
The company is the nation’s leading managed care organization by Blue Cross Blue Shield membership, insuring around 45.4 million medical members across commercial, Medicaid, Medicare Advantage, and individual ACA markets, with a growing healthcare services arm called Carelon that spans pharmacy benefits, risk-based care programs, and behavioral health.
The beat was not a one-time windfall.
CEO Gail Boudreaux said on the Q1 call: “While it is still early in the year, the trends we are seeing give us increased confidence in the trajectory of the business.”
Two distinct forces drove the outperformance: underlying business favorability, concentrated primarily in better claims experience across health benefits, and individual ACA seasonality tied to a higher-than-expected share of members choosing bronze-tier plans.
Elevated medical cost trend had pressured the entire managed care sector for more than two years, and Elevance Health stock spent most of the past twelve months reflecting that pressure, touching a 52-week low of around $274 before recovering toward the current level near $395.
The benefit expense ratio came in at 86.8% for the quarter, better than the analyst estimate of 87.01%, a signal that the company’s cost management actions are beginning to show measurable results.
Elevance raised its full-year 2026 adjusted diluted EPS guidance to at least $26.75, up from at least $25.50 prior, and reiterated its operating cash flow outlook of at least $5.5 billion.
The company also noted that CarelonRx, its pharmacy benefit management business, is running ahead of plan for 2027 sales momentum, with two national account wins already secured, and that integrated medical and pharmacy clients are seeing savings of more than $100 per member per month.
Is Elevance Health Stock Undervalued After Q1 2026 Earnings?
Twenty-two analysts cover Elevance Health stock, with 12 rating it a Buy, 3 an Outperform, and 7 a Hold — no sells anywhere in the stack.
The street mean target stands at around $401, representing only modest upside from the current price of around $395.
That tight spread tells a specific story: the consensus has not yet re-rated aggressively following the Q1 beat, even as Mizuho raised its price target to around $435 and UBS lifted its target to around $460 in the days following earnings.
The strongest bull case from covered analysts sits at around $498, implying more than 26% upside from current levels if the margin recovery story fully plays out.
The key variable the street is watching is whether Q2 holds the improvement in medical cost trend, since Q2 has historically been the quarter that can surprise managed care companies as claims from Q1 process through May.
Elevance’s own guidance builds in conservative assumptions: the company said underlying cost trend remains at the high end of the mid-single-digit range in Medicaid, and it is not relying on a more favorable trend environment to support the $26.75 guide.
Free cash flow is the metric that most directly proves the thesis.
ELV generated $3.17 billion in free cash flow in 2025, down from $4.55 billion in 2024, a compression that tracked with the margin pressure across the sector. The consensus estimate for 2026 calls for FCF recovery to around $6.21 billion, roughly double the 2025 level, implying that the market-wide managed care drawdown suppressed cash generation and that normalization is already embedded in forward estimates.
With consensus EPS for 2026 estimated at $26.91 — below the company’s own guidance floor of $26.75 — the setup is one where guidance beats rather than misses are the likelier outcome as the year progresses.
What TIKR’s $534 Mid-Case Target on ELV Stock Requires — and Where the Risk Lives
TIKR’s base case values Elevance Health at approximately $534 by December 2030, implying around 35% total return from the current price of approximately $395, or roughly 7% annualized over the next 4 and a half years.
The mid case assumes around 3% annual revenue growth through 2035, a net income margin of around 3.3%, and EPS growing at around 6% annually, with a slight multiple compression of around 1.2% per year as the sector re-rates toward normalized earnings.
The key tension is whether the company’s 12% adjusted EPS growth target for 2027 — set off a revised 2026 baseline of at least $25.75 — can be achieved given ongoing Medicaid margin pressure, uncertain ACA enrollment dynamics, and the phased rollout of Medicaid work requirements beginning in 2027.
In the low case, slower revenue growth of around 3% and tighter margins would push Elevance Health stock to approximately $595 by December 2034, delivering roughly 51% total return, or around 5% annualized. In the mid case, the stock reaches approximately $738 by December 2034, returning around 87% in total and around 8% annually.
In the high case, with around 3.3% revenue growth and a net income margin of around 3.4% sustained through the period, the stock reaches approximately $885, delivering roughly 124% total return and around 10% annualized.
Every scenario assumes a multiple contraction from current levels. The argument for Elevance Health stock is not a re-rating story — it is an earnings recovery story, and the Q1 data says that recovery is already underway.
Is Elevance Health stock a buy right now?
The consensus leans toward buy: 12 of 22 covering analysts rate ELV a Buy, with 3 more at Outperform and no sells. The street mean target is around $401, modestly above the current price of around $395, but Mizuho recently raised its target to around $435 and UBS to around $460 following Q1 results.
The TIKR mid-case model puts fair value at around $534 by December 2030, implying meaningful long-term upside if the 2026 earnings recovery holds.
The key variable to watch is Q2 claims development, which will confirm or complicate the Q1 medical cost improvement.
Should You Invest in Elevance Health, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Elevance Health stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Elevance Health alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ELV stock on TIKR for Free →
